WO2008138533A1 - Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines - Google Patents
Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines Download PDFInfo
- Publication number
- WO2008138533A1 WO2008138533A1 PCT/EP2008/003679 EP2008003679W WO2008138533A1 WO 2008138533 A1 WO2008138533 A1 WO 2008138533A1 EP 2008003679 W EP2008003679 W EP 2008003679W WO 2008138533 A1 WO2008138533 A1 WO 2008138533A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vaccinia virus
- virus
- vaccinia
- eluted
- ligand
- Prior art date
Links
- 241000700618 Vaccinia virus Species 0.000 title claims abstract description 199
- 238000000746 purification Methods 0.000 title claims abstract description 55
- 229960005486 vaccine Drugs 0.000 title claims description 38
- 206010046865 Vaccinia virus infection Diseases 0.000 title description 28
- 208000007089 vaccinia Diseases 0.000 title description 28
- 241000700605 Viruses Species 0.000 claims abstract description 106
- 239000002245 particle Substances 0.000 claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 75
- 238000002360 preparation method Methods 0.000 claims abstract description 39
- 239000003446 ligand Substances 0.000 claims description 64
- 239000011159 matrix material Substances 0.000 claims description 45
- 230000027455 binding Effects 0.000 claims description 36
- 239000012528 membrane Substances 0.000 claims description 36
- 238000011068 loading method Methods 0.000 claims description 33
- 239000007790 solid phase Substances 0.000 claims description 33
- 229960002897 heparin Drugs 0.000 claims description 29
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 28
- 229920000669 heparin Polymers 0.000 claims description 28
- 229920002971 Heparan sulfate Polymers 0.000 claims description 26
- 239000000356 contaminant Substances 0.000 claims description 26
- 238000005406 washing Methods 0.000 claims description 24
- 208000015181 infectious disease Diseases 0.000 claims description 20
- 230000001965 increasing effect Effects 0.000 claims description 18
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 11
- 239000007791 liquid phase Substances 0.000 claims description 10
- 229920002678 cellulose Polymers 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 239000001913 cellulose Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 239000011148 porous material Substances 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 4
- 229960002442 glucosamine Drugs 0.000 claims description 4
- -1 glucosamine glycan Chemical class 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 238000005342 ion exchange Methods 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000004071 biological effect Effects 0.000 abstract description 11
- 238000009776 industrial production Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 69
- 108090000623 proteins and genes Proteins 0.000 description 41
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical group P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 35
- 239000002953 phosphate buffered saline Substances 0.000 description 35
- 102000004169 proteins and genes Human genes 0.000 description 35
- 210000004379 membrane Anatomy 0.000 description 34
- 108020004414 DNA Proteins 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 31
- 238000010828 elution Methods 0.000 description 30
- 101150080480 A27L gene Proteins 0.000 description 27
- 101100268532 Vaccinia virus (strain Western Reserve) VACWR150 gene Proteins 0.000 description 27
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 21
- 210000002845 virion Anatomy 0.000 description 20
- 108010052285 Membrane Proteins Proteins 0.000 description 18
- 102000018697 Membrane Proteins Human genes 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- 241000700647 Variola virus Species 0.000 description 13
- 238000002835 absorbance Methods 0.000 description 13
- 229910019142 PO4 Inorganic materials 0.000 description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 12
- 239000010452 phosphate Substances 0.000 description 12
- 230000003993 interaction Effects 0.000 description 11
- 238000011084 recovery Methods 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 150000002016 disaccharides Chemical group 0.000 description 10
- 238000012544 monitoring process Methods 0.000 description 10
- 230000002458 infectious effect Effects 0.000 description 9
- 238000011529 RT qPCR Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 7
- 239000012160 loading buffer Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000002731 protein assay Methods 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000013017 sartobind Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 239000012512 bulk drug substance Substances 0.000 description 5
- 238000011026 diafiltration Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229910021653 sulphate ion Inorganic materials 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 238000001261 affinity purification Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 238000011020 pilot scale process Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 108010022901 Heparin Lyase Proteins 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 108010008038 Synthetic Vaccines Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 241000870995 Variola Species 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000008029 eradication Effects 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical class O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 229940124551 recombinant vaccine Drugs 0.000 description 3
- 229940083538 smallpox vaccine Drugs 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 208000001203 Smallpox Diseases 0.000 description 2
- 238000012290 Total DNA Assay Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000003055 low molecular weight heparin Substances 0.000 description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 239000004953 Aliphatic polyamide Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101710127879 Heparin lyase I Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229930182473 O-glycoside Natural products 0.000 description 1
- 150000008444 O-glycosides Chemical class 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000005585 Poxviridae Infections Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000287219 Serinus canaria Species 0.000 description 1
- 241000202917 Spiroplasma Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 101900243332 Vaccinia virus Protein A36 Proteins 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229920003231 aliphatic polyamide Polymers 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000004760 aramid Substances 0.000 description 1
- 229920003235 aromatic polyamide Polymers 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000005640 glucopyranosyl group Chemical group 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 101150098203 grb2 gene Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000011140 membrane chromatography Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000005871 monkeypox Diseases 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920002620 polyvinyl fluoride Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940126580 vector vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
Definitions
- the present invention provides methods for purification of native and recombinant Vaccinia virus and/or Vaccinia virus particles. According to the present invention, the use of this method facilitates purification of a vaccine with high efficiency and desirable yield in terms of purity, biological activity, and stability and is furthermore applicable for an aseptic production process in lab-, pilot-, and industrial-scale.
- a vaccine vector is a living organism that does not cause disease itself, but which spreads infection by "carrying" pathogens (agents that cause disease) from one host to another.
- a vaccine vector is a weakened or killed version of a virus or bacterium that carries an inserted antigen (coding for a protein recognized by the body as foreign) from a disease-causing agent to the subject being vaccinated.
- a vaccine vector delivers the antigen in a natural way into the body and stimulates the immune system into acting against a "safe infection.” The immune system is led into generating an immune response against the antigen that protects the vaccinated subject against future "risky infections.”
- a recombinant modified virus can be used as the vehicle or vaccine vector for delivering genetic material to a cell.
- genetic information is transcribed and translated into proteins, including the inserted antigen targeted against a specific disease.
- Treatment is successful if the antigen delivered by the vector into the cell produces a protein, which induces the body's immune response against the antigen and thereby protects against the disease.
- a viral vector can be based on an attenuated virus, which cannot replicate in the host but is able to introduce and express a foreign gene in the infected cell.
- the virus or the recombinant virus is thereby able to make a protein and display it to the immune system of the host.
- Some key features of viral vectors are that they can elicit a strong humoral (B-cell) and cell-mediated (T- cell) immune response.
- Viral vectors are commonly used by researchers to develop vaccines for the prevention and treatment of infectious diseases and cancer, and of these, poxviruses (including canary pox, vaccinia, and fowl pox) are the most common vector vaccine candidates.
- Pox viruses are a preferred choice for transfer of genetic material into new hosts due to the relatively large size of the viral genome (appr. 150/200 kb) and because of their ability to replicate in the infected cell's cytoplasm instead of the nucleus, thereby minimizing the risk of integrating genetic material into the genome of the host cell.
- pox viruses the vaccinia and variola species are the two best known.
- the virions of pox viruses are large as compared to most other animal viruses (for more details see Fields et al., eds., Virology, 3 rd Edition, Volume 2, Chapter 83, pages 2637 ff).
- Variola virus is the cause of smallpox.
- vaccinia virus does not normally cause systemic disease in immune-competent individuals and it has therefore been used as a live vaccine to immunize against smallpox.
- Successful worldwide vaccination with Vaccinia virus culminated in the eradication of smallpox as a natural disease in the 1980s (The global eradication of smallpox. Final report of the global commission for the certification of smallpox eradication; History of Public Health, No. 4, Geneva: World Health Organization, 1980). Since then, vaccination has been discontinued for many years, except for people at high risk of poxvirus infections (for example, laboratory workers).
- Vaccinia virus is highly immune-stimulating and provokes strong B- (humoral) and T-cell mediated immunity to both its own gene products and to any foreign gene product resulting from genes inserted in the Vaccinia genome.
- Vaccinia virus is therefore seen as an ideal vector for vaccines against smallpox and other infectious diseases and cancer in the form of recombinant vaccines.
- Most of the recombinant Vaccinia viruses described in the literature are based on the fully replication competent Western Reserve strain of Vaccinia virus. It is known that this strain has a high neurovirulence and is thus poorly suited for use in humans and animals (Morita et al. 1987, Vaccine 5, 65-70).
- MVA Modified Vaccinia virus Ankara
- CVA Chorioallantois Vaccinia Ankara
- CEF chicken embryo fibroblast
- MVA virus strains deposited in compliance with the requirements of the Budapest Treaty are strains MVA 572, MVA 575, and MVA-BN deposited at the European Collection of Animal Cell Cultures (ECACC), Salisbury (UK) with the deposition numbers ECACC V94012707, ECACC V00120707 and ECACC V00083008, respectively, and described in U.S. Patent Nos. 7,094,412 and 7,189,536.
- MVA is distinguished by its great attenuation profile compared to its precursor CVA. It has diminished virulence or infectiousness, while maintaining good immunogenicity.
- the MVA virus has been analyzed to determine alterations in the genome relative to the wild type CVA strain. Six major deletions of genomic DNA (deletion I 1 II, III, IV, V, and Vl) totaling 31 ,000 base pairs have been identified (Meyer, H. et al. 1991 , J. Gen. Virol. 72, 1031-1038). The resulting MVA virus became severely host-cell restricted to avian cells. The excellent properties of the MVA strain have been demonstrated in extensive clinical trials ( Mayr, A. et al. 1978, ZbI. Bakt. Hyg. I, Abt. Org.
- MVA-BN ® is a virus used in the manufacturing of a stand-alone third generation smallpox vaccine. MVA-BN ® was developed by further passages from MVA strain 571/572. To date, more than 1500 subjects including subjects with atopic dermatitis (AD) and HIV infection have been vaccinated in clinical trials with MVA-BN ® based vaccines.
- AD topic dermatitis
- Vaccinia virus as a tool for preparation of recombinant vaccines has additionally created significant industrial interest in methods for manufacturing (growth and purification) of native Vaccinia viruses and recombinant-modified Vaccinia viruses.
- Viruses used in the manufacturing of vaccines or for diagnostic purposes can be purified in several ways depending on the type of virus.
- purification of pox viruses including Vaccinia viruses and recombinant- modified Vaccinia viruses has been carried out based on methods separating molecules by means of their size differences.
- the primary purification by means of size separation has been supplemented by secondary methods such as enzymatic digestion of DNA (e.g. Benzonase treatment).
- the primary purification of Vaccinia viruses and recombinant-modified Vaccinia viruses has been performed by sucrose cushion or sucrose gradient centrifugation at various sucrose concentrations. Recently, ultrafiltration has also been applied either alone or in combination with sucrose cushion or sucrose gradient purification.
- Vaccinia Viruses-based vaccines have in general been manufactured in primary CEF (Chicken Embryo Fibroblasts) cultures. Vaccines manufactured in primary CEF cultures are generally considered safe as regards residual contaminants. First, it is scientifically unlikely that primary cell cultures from healthy chicken embryos should contain any harmful contaminants (proteins, DNA). Second, millions of people have been vaccinated with vaccines manufactured on CEF cultures without any adverse effects resulting from the contaminants (CEF proteins and CEF DNA). There is, therefore, no regulatory requirement for the level of host cell contaminants in vaccines manufactured in primary CEF cultures, but for each vaccine the manufacturer must document its safety.
- primary CEF Chicken Embryo Fibroblasts
- the regulatory concern for vaccines manufactured in primary CEF cultures relates to the risk of adventitious agents (microorganisms (including bacteria, fungi, mycoplasma/spiroplasma, mycobacteria, rickettsia, viruses, protozoa, parasites, TSE agent) that are inadvertently introduced into the production of a biological product).
- adventitious agents microorganisms (including bacteria, fungi, mycoplasma/spiroplasma, mycobacteria, rickettsia, viruses, protozoa, parasites, TSE agent) that are inadvertently introduced into the production of a biological product).
- the level of CEF protein may be up to 1 mg/dose and the CEF DNA level may exceed 10 ⁇ g/dose of 1 x 10 8 as measured by the TCI D50. These levels are considered acceptable from a safety and regulatory perspective as long as the individual vaccine manufacturer demonstrates that the levels to be found in the Final Drug Product (FDP) are safe at the intended human indications. Due to the risk of presence of adventitious agents in vaccines manufactured in primary cell cultures and the associated need for extensive, expensive biosafety testing of each vaccine batch manufactured, there is a strong stimulus for the vaccine industry to change to continuous cell lines. Once a continuous cell line has been characterized the need for testing for adventitious agents of the production batches is minimal.
- vaccinia virions are able to bind to heparin through the surface protein A27L (Chung et al. 1998, J. Virol. 72, 1577-1585). It has further been suggested that affinity chromatography (Zahn, A and Allain, J.-P. 2005, J. Gen. Virol. 86, 677-685) may be used as basis for purification of certain virus preparations.
- Vaccinia virions are far too large to be effectively loaded onto commercially available heparin columns, e.g., the Hi-Trap heparin column from Amersham Biosciences used by others (Zahn, A and Allain, J.-P. 2005, J. Gen. Virol. 86, 677-685) for lab-scale purification of Hepatitis C and B viruses.
- the Vaccinia virion volume is approximately 125 times larger than Hepatitis virion. (The diameter of the Vaccinia virus is, thus, appr. 250 nm as compared with the hepatitis C and B virions diameter being appr. 50nm).
- available matrices as, e.g., used in the column-based approach may not allow for adequate entrance of virions into the matrix, loading of sufficient amounts of virus particles or sufficiently rapid flow through the column to meet the needs for industrial scale purification.
- Zahn and Allain worked with virus load up to 1 x 10 6 in up to 1.0 ml volume.
- virus loading capacity higher than 1 x 10 11 preferably up 1 x 10 13 , in volumes higher than 5 L, preferably up to 50 L, is needed.
- For industrial purification of Vaccinia virus loading capacity higher than 1 x 10 13 preferably higher than 1 x 10 14 in volumes higher than 300 L, preferably higher than 600 L 1 is needed.
- the large size of the Vaccinia virus may prevent effective steric access between the specific surface proteins of the virions and the ligand immobilized to the matrix.
- Currently described lab-scale methods of use for purification of small virus particles may therefore not be industrially applicable to purification of Vaccinia virus.
- elution of bound Vaccinia virus may require more harsh and therefore potentially denaturing conditions to elute and recover the Vaccinia virus particles in a biologically effective form in high yields.
- the matrix, the ligand design, the method of ligand immobilization, and the ligand density may therefore require careful design to mediate an effective binding of the Vaccinia virus and to permit an effective elution of biologically active Vaccinia virus particles.
- Vaccinia virions are too large to be sterile filtered.
- the method used in this invention has therefore been developed by to be applicable for an aseptic industrial-scale manufacturing process in a way ensuring full compliance with regulatory requirements regarding sterility of vaccines.
- the column substituted with the ligand should be applicable for sterilization-in-place or should be available as a pre- sterilized unit.
- the present invention is directed to a method for the purification of biologically active Vaccinia virus comprising: a) loading a solid-phase matrix, to which a ligand is attached, with a
- Vaccinia virus contained in a liquid-phase culture; b) washing the matrix, and c) eluting the virus.
- the ligand is a substance that, on the one hand, can be attached to the solid- phase matrix, e. g., by binding or coupling thereto and that, on the other hand, is able to form a reversible complex with the Vaccinia virus. Thus, by interacting with the virus, the virus is reversibly retained.
- the ligand can be a biological molecule as, for example, a peptide and/or a lectin and/or an antibody and/or, preferably, a carbohydrate.
- the ligand may also comprise or consist of sulfate. In a further embodiment, the ligand comprises one or more negatively charged sulfate groups.
- the ligand can also be a hydrophobic molecule as, for example, an aromatic phenyl group.
- the ligand can be attached to the matrix directly, e.g, by direct binding, or can be attached to the matrix indirectly though another molecule, e.g. by coupling through a linker or spacer.
- the solid-phase matrix can be a gel, bead, well, membrane, column, etc.
- the solid-phase comprises or is a membrane, in particular a cellulose membrane.
- a broad range of other polymers modified with specific groups capable to bind the virus can be used. Preferred are hydrophilic polymers.
- cellulose derivatives cellulose esters and mixtures thereof, cellulose hydrate, cellulose acetate, cellulose nitrate); aggarose and its derivatives; other polysaccachrides like chitin and chitosan; polyolefines (polypropylene); polysulfone; plolyethersulfone; polystyrene; aromatic and aliphatic polyamides; polysulfonamides; halogenated polymers (polyvinylchlorid, polyvinylfluorid, polyvinylidenfluorid); polyesters; homo- and copolymers of acrylnitrile.
- cellulose derivatives cellulose esters and mixtures thereof, cellulose hydrate, cellulose acetate, cellulose nitrate
- aggarose and its derivatives other polysaccachrides like chitin and chitosan
- polyolefines polypropylene
- polysulfone plolyethersulfone
- the method and further embodiments of the invention can overcome the limitations of currently known methods preventing industrial-scale, effective purification of Vaccinia virus particles with high biological activity and purity.
- the method is superior in terms of yield, process time, purity, recovery of biologically active Vaccinia virus particles and costs to existing pilot-scale methods for purification of Vaccinia virus particles, which are primarily based on sucrose-cushion centrifugation and/or diafiltration or non-specific ion- exchange chromatography. It is also superior in terms of yield, process time, purity, recovery of biologically active Vaccinia virus particles, and costs to the only existing large-scale method for purification of Vaccinia virus particles, which is based on ultrafiltration, enzymatic DNA degradation, and diafiltration.
- Vaccinia virus can be purified under aseptic conditions to obtain a biologically active, stable, and highly pure virus preparation in high yield.
- the Vaccinia viruses can be native or recombinant.
- the present invention provides an improved method for aseptic purification of Vaccinia viruses in lab-, pilot-, and, preferably, in industrial-scale, leading to a biologically active, stable and highly pure virus preparation in high yield.
- This invention provides a more time-effective and cost-effective process for purification of Vaccinia viruses and recombinant Vaccinia viruses, Modified Vaccinia virus Ankara (MVA) and recombinant MVA, MVA-BN ® and recombinant MVA-BN ® , leading to a biologically active, stable and highly pure virus preparation in high yield.
- VVA Modified Vaccinia virus Ankara
- this invention provides virus preparations produced by the method of the invention.
- Vaccinia virus or recombinant Vaccinia virus or Modified Vaccinia virus Ankara (MVA) or recombinant MVA or MVA-BN ® or recombinant MVA-BN ® , all preferably obtained by the method according to the present invention, for the preparation of a pharmaceutical composition, in particular a vaccine, is also an embodiment of the invention.
- the virus and/or pharmaceutical preparation is preferably used for the treatment and/or the prevention of cancer and/or of an infectious disease.
- VVA Modified Vaccinia virus Ankara
- an "attenuated virus” is a strain of a virus whose pathogenicity has been reduced compared to its precursor, for example by serial passaging and/or by plaque purification on certain cell lines, or by other means, so that it has become less virulent because it does not replicate, or exhibits very little replication, but is still capable of initiating and stimulating a strong immune response equal to that of the natural virus or stronger, without producing the specific disease.
- glucosamine glycan in particular heparan sulfate or heparin, or a GAG-like substance is used as ligand.
- GAGs glycosaminoglycans
- GAGs are long un-branched polysaccharides consisting of a repeating disaccharide unit. Some GAGs are located on the cell surface where they regulate a variety of biological activities such as developmental processes, blood coagulation, tumor metastasis, and virus infection.
- GAG-like agents are defined as any molecule which is similar to the known GAGs, but can be modified, for example, by the addition of extra sulfate groups (e.g. over-sulfated heparin).
- GAG-like ligands can be synthetic or naturally occurring substances. Additionally, the term “GAG-like ligands” also covers substances mimicking the properties of GAGs as ligands in ligand-solid-phase complexes.
- SRC Sulfated Reinforced Cellulose
- Stabilized Reinforced Cellulose membranes can be obtained, for example, from Sartorius AG.
- Bulk Drug Substance refers to the purified virus preparation just prior to the step of formulation, fill and finish into the final vaccine.
- Biological activity is defined as Vaccinia virus virions that are either 1 ) infectious in at least one cell type, e.g. CEFs, 2) immunogenic in humans, or 3) both infectious and immunogenic.
- a "biologically active" Vaccinia virus is one that is either infectious in at least one cell type, e.g. CEFs, or immunogenic in humans, or both.
- the Vaccinia virus is infectious in CEFs and is immunogenic in humans.
- contaminants cover any unwanted substances which may originate from the host cells used for virus growth (e.g. host cell DNA or protein) or from any additives used during the manufacturing process including upstream (e.g. gentamicin) and downstream (e.g. Benzonase).
- host cells used for virus growth e.g. host cell DNA or protein
- upstream e.g. gentamicin
- downstream e.g. Benzonase
- continuous cell culture or immortalized cell culture
- continuous or immortalized cell culture describes cells that have been propagated in culture since the establishment of a primary culture, and they are able to grow and survive beyond the natural limit of senescence. Such surviving cells are considered as immortal.
- the term immortalized cells were first applied for cancer cells which were able to avoid apoptosis by expressing a telomere- lengthening enzyme.
- Continuous or immortalized cell lines can be created e.g. by induction of oncogenes or by loss of tumor suppressor genes.
- heparan sulfate is a member of the glycosaminoglycan family of carbohydrates. Heparan sulfate is very closely related in structure to heparin, and they both consist of repeating disaccharide units which are variably sulfated. The most common disaccharide unit in heparan sulfate consists of a glucuronic linked to N-acetyl glucosamine, which typically makes up approx. 50% of the total disaccharide units.
- heparin is a member of the glycosaminoglycan family of carbohydrates. Heparin is very closely related in structure to heparan sulfate, and they both consist of repeating disaccharide units which are variably sulfated. In heparin, the most common disaccharide unit consists of a sulfated iduronic acid linked to a sulfated glucopyranosyl.
- “industrial scale” or large-scale for the manufacturing of Vaccinia virus or recombinant Vaccinia virus-based vaccines comprises methods capable of providing a minimum of 50,000 doses of 1.0 x 10 8 virus particles (total minimum 5.0 x 10 12 virus particles) per batch (production run). Preferably, more than 100,000 doses of 1.0 x 10 8 virus particles (total minimum 1.0 x 10 13 virus particles) per batch (production run) are provided.
- “lab-scale” comprises virus preparation methods of providing less than 5,000 doses of 1.0 x 10 8 virus particles (total less than 5.0 x 10 11 virus particles) per batch (production run).
- pilot-scale comprises virus preparation methods of providing more than 5,000 doses of 1.0 x 10 8 virus particles (total more than 5.0 x 10 11 virus particles), but less than 50,000 doses of 1.0 x 10 8 virus particles (total minimum 5.0 x 10 12 virus particles) per batch (production run).
- Primary cell culture refers to the stage where the cells have been isolated from the relevant tissue (e.g. from specific pathogen free (SPF) hens eggs), but before the first sub-culture. This means that the cells have not been grown or divided any further from the original origin.
- relevant tissue e.g. from specific pathogen free (SPF) hens eggs
- Purity of the Vaccinia virus preparation or vaccine is investigated in relation to the content of the impurities DNA, protein, Benzonase, and gentamicin.
- the purity is expressed as specific impurity, which is the amount of each impurity per dose (e.g. ng DNA/dose).
- purification of a Vaccinia virus preparation refers to the removal or measurable reduction in the level of some contaminant in a Vaccinia virus preparation.
- Recombinant Vaccinia virus is a virus, where a piece of foreign genetic material (from e.g. HIV virus) has been inserted into the viral genome. Thereby, both the Vaccinia virus genes and any inserted genes will be expressed during infection of the Vaccinia virus in the host cell.
- Stability means a measure of how the quality of the virus preparation (Bulk Drug Substance (BDS) or Final Drug Product (FDP)) varies with time under the influence of a variety of environmental factors such as temperature, humidity and lights, and establishes a retest period for the BDS or a shelf-life for the FDP at recommended storage conditions (Guidance for industry Q1A (R2).
- Virus preparation is a suspension containing virus.
- the suspension could be from any of the following steps in a manufacturing process: after virus growth, after virus harvest, after virus purification (typically the BDS) 1 after formulation, or the final vaccine (FDP).
- vaccinia virus forms refer to the three different types of virions produced by infected target cells: Mature virions (MV), wrapped virions (WV), and extra-cellular virions (EV) (Moss, B. 2006, Virology, 344:48-54).
- the EV form comprises the two forms previously known as cell-associated enveloped virus (CEV), and extra-cellular enveloped virus (EEV) (Smith, G. L. 2002, J. Gen. Virol. 83: 2915-2931 ).
- the MV and EV forms are morphologically different since the EV form contains an additional lipoprotein envelope. Furthermore, these two forms contain different surface proteins (see Table 1 ), which are involved in the infection of the target cells by interaction with surface molecules on the target cell, such as glycosaminglycans (GAGs) (Carter, G. C. et al. 2005, J. Gen. Virol. 86: 12791290).
- GAGs glycosaminglycans
- the invention involves use of the purification of all forms of Vaccinia Virus.
- Vaccinia virions contain different surface proteins, which are involved in the infection of the target cells by interaction with surface molecules on the target cell, such as glycosaminglycans (GAGs) (Carter, G. C. et al. 2005, J. Gen. Virol. 86: 1279-1290). These surface proteins will as mentioned supra be referred to as receptors.
- GAGs glycosaminglycans
- p14 or A27L (the latter term will be used in this application) is involved in the initial attachment of the virions to the target cell. A27L binds to GAG structures on the target cell prior to entry into the cell (Chung C. et al. 1998, J. Virol.
- GAG heparan sulfate
- GAGs glycosaminglycans
- GAGs are negatively charged molecules containing sulfate groups.
- the A27L protein is located on the surface of the virions and is anchored to the membrane by interaction with the A17L protein (Rodriguez D. et al. 1993, J. Virol. 67: 3435-3440) (Vazquez M. et al. 1998, J. Virol. 72: 10126-10137). Therefore, the interaction between A27L and AI17L can be kept intact during isolation in order to retain full biological activity of the virions.
- the invention encompasses the use of the affinity interaction between the A27L surface protein on the MV form and glucosaminglycans, in particular Heparan Sulfate, for purification of the MV form of Vaccinia Virus.
- ligand refers both to a receptor on a target cell and to the specific binding structure attached to a solid-phase matrix used for purification of Vaccinia.
- the same principle as described above can be applied to interactions between other target cell surface structures and other Vaccinia surface proteins of the MV form participating in the Vaccinia virus 1 recognition of, attachment to, entry into and/or fusion with the target cell (see Table 1 ).
- Other WV and EV surface proteins are summarized in Table 1.
- the entire A27L protein, or fragments thereof containing the binding region for the GAG ligand can be used as agents to elute Vaccinia viruses-GAG complexes from a solid-phase column of the invention. Fragments can be readily generated by routine molecular techniques and screened for their ability to dissociate Vaccinia viruses-GAG complexes using routine techniques known in the art, such as by measuring eluted, biologically active virus.
- the presumed native GAG-ligand for the MV form of Vaccinia is Heparan Sulfate (HS) and can be one of the suitable ligands.
- the invention also comprises use of "non-native" ligands for purification of Vaccinia virus.
- non-native ligands are compounds with a high degree of structural and/or conformational similarity to native ligands.
- Heparin which is a close analogue to the native ligand for A27L, HS, can be used for affinity- purification of MV form by interaction with the A27L surface protein, see further below. Heparin has been shown to partially inhibit the binding between target cells and Vaccinia virus and can therefore also be used for affinity purification of the MV form of Vaccinia.
- Other GAG-ligands and GAG-like ligands can also be used.
- Heparan Sulfate used for affinity purification of the MV form of Vaccinia, binds A27L on biologically active Vaccinia viruses, but does not bind inactive Vaccinia viruses or Vaccinia virus fragments.
- the ligand makes possible the elution of the bound Vaccinia virus under such mild conditions that the Vaccinia virus fully retain their biologically activity. This means that the structure of A27L and the interaction between A27L and A17L can be kept intact.
- the binding and elution characteristics for the GAG-ligand substituted matrix depend not only on the individual characteristics of the matrix and ligand, but also on the interplay between the two.
- the binding strength between the target GAG- ligand structure and the A27L surface protein on the Vaccinia virus can be altered, which can be used to e.g. enhance the capture or ease the elution.
- the matrix in the form of a chromatography gel or membrane to be used for the purification preferably:
- the solid phase matrix is a gel or membrane with a pore size of 0.25 ⁇ m, preferably of more than 0.25 ⁇ m, more preferably of 1.0- 3.0 ⁇ m demonstrating a linear flow rate under actual purification conditions of 10 cm/min, preferably 20 cm/min.
- the pore size of the matrix can be 0.25- 0.5 ⁇ m, 0.5-0.75 ⁇ m, 0.75-1.0 ⁇ m, 1.0-2.0 ⁇ m, 2.0-3.0 ⁇ m, or greater than 3.0 ⁇ m.
- the virus harvest from the upstream virus growth process is loaded in a crude (unpurified) form with a flow rate of 10cm/min, preferably 20cm/min at a virus concentration of 10 6 virions per ml_ in pilot scale and 10 7 virions per ml_ in industrial scale.
- a flow rate of 10cm/min preferably 20cm/min at a virus concentration of 10 6 virions per ml_ in pilot scale and 10 7 virions per ml_ in industrial scale.
- Step 1 Loading of Vaccinia virus or recombinant virus onto a solid- phase matrix
- Loading to the solid phase with, e.g., Heparane Sulphate or another GAG or GAG-like structure attached as ligand, can be performed by a batch-, column- or membrane approach.
- the membrane approach can have some benefits, specifically for large bio- molecules, in particular for large viruses like Vaccinia viruses: For example, large pore sizes and the availability of the ligand on the surface of the membrane allow high binding capacities of even large viral particles.
- the membrane approach is, thus, a preferred embodiment of the present invention.
- the Vaccinia virus or recombinant virus to be isolated is present in a liquid phase.
- the Vaccinia virus or recombinant virus gets close to the GAG or GAG-like ligand the Vaccinia virus will bind specifically to or be "captured by" the GAG-ligand, thereby the Vaccinia virus or recombinant Vaccinia virus can be temporarily immobilized on the solid phase, while the contaminants will remain in the liquid phase.
- Step 2 Washing of the solid phase to remove contaminants
- the host cell contaminants in particular host cell DNA and proteins
- the solid phase to which the Vaccinia virus is bound, with an appropriate washing medium.
- Step 3 Eluting the Vaccinia virus or recombinant virus by specific or non-specific agents
- the biologically active Vaccinia viruses or recombinant viruses can be eluted.
- the elution of the captured Vaccinia virus can be performed, for example, by:
- agents agents non-specifically disrupting the electrostatic interaction between, e.g., the negatively charged GAG-ligand and the positively charged A27L surface protein (to be called non-specific agents).
- the Vaccinia virus is eluted with GAG or a GAG-like ligand or part thereof, with the GAG-binding domain of A27L or part thereof, and/or with an O-glycoside-binding cleaving enzyme.
- Elution of the virus is, further, preferably performed with sodium chloride, more preferably by an increasing NaCI concentration gradient ranging from 0.15 M to 2.0 M.
- Pre-treatment Prior to loading on the solid phase, a pre-treatment of the virus suspension can be performed, specifically in order to remove contaminants from the Vaccinia virus in the liquid-phase culture. Pre-treatment can be one or more of the following steps either alone or in combination:
- the pH value of the viral suspension is decreased just prior to loading in order to improve the binding of the virus particle to the ligand.
- the pH value of the viral suspension can be decreased from appr. pH 7.0-8.0 to 4.0-6.9, in particular to pH 4.0, 4.2, 4.4, 4.5, 4.6, 4.8, 5.0, 5.2, 5.4, 5.5, 5.6, 5.8, 6.0, 6.2, 6.4, 6.5, 6.6, 6.8, 6.9.
- the pH value is decreased from pH 7.0-8.0 to pH 5.8.
- the pH value is again increased to pH 7.0-8.0, in particular to pH 7.0, 7.2, 7.4, 7.5, 7.6, 7.8, 8.0, preferably to pH 7.7, in order to improve the stability of the viral particles.
- post-treatment can be performed to enhance the purity of the virus preparation.
- the post-treatment could be ultra/diafiltration for further removal of impurities and/or specific or non-specific agents used for elution.
- the pH value after elution of the virus in particular to a pH value of up to 9 or more, in particular to pH 7.5, 7.6, 7.8, 8.0, 8.2, 8,4, 8.5, 8.6, 8.8, 9.0, 9.2, 9.4, 9.5, 9.6, 9.8, 10.0, 10.2, 10.4, 10.5.
- the pH value is increased from, in particular, pH 7.0, 7.2, 7.4, 7.5, 7.6, 7.8, 8.0, preferably pH 7.7, to pH 9.0.
- the Vaccinia virus sample contains host-cell DNA in the range of 10-20 ⁇ g per dose (1 x10 8 TCID 50 - 3.2x10 8 TCID 50 ), preferably 10 ng, more preferably less than 10 ng host-cell DNA per 10 8 virus particles after performance of the purification steps according to the invention, i.e. after elution of the virus.
- the invention provides a more time-effective and cost- effective process for purification of Vaccinia viruses and recombinant-modified Vaccinia viruses in higher yield, comprising one or more of the following steps: a) loading a solid-phase matrix with a liquid-phase virus preparation, wherein the solid-phase matrix comprises a ligand appropriate for interacting with the virus, e.g. by reversibly binding the virus b) washing of the matrix, and c) eluting the virus.
- the method comprises the following steps: a. Loading a column, membrane, filter or similar solid-phase matrix comprising one or more appropriate virus-binding ligands with a liquid-phase virus preparation, b. Washing of the matrix with an appropriate solvent to remove contaminants, and c. Eluting the Vaccinia virus with an appropriate solvent to achieve a highly pure, biologically active, stable virus preparation.
- the method comprises the following steps:
- a Loading a column, membrane, filter or similar solid-phase matrix comprising one or more appropriate glucosamine glycan (GAG) or GAG-like virus-binding ligands with a liquid-phase virus preparation
- a Loading a column, membrane, filter or similar solid-phase matrix comprising one or more appropriate glucosamine glycan (GAG) or GAG-like virus-binding ligands with a liquid-phase virus preparation
- GAG glucosamine glycan
- GAG-like virus-binding ligands with a liquid-phase virus preparation
- b Washing of the matrix with an appropriate solvent to remove contaminants
- c Eluting the Vaccinia virus with a solvent resulting in an concentration gradient of a non-specific eluent such as NaCI, H+ or of specific eluent such as a GAG-like compound or and A27L peptide or peptide-fragment to achieve a highly pure, biologically active
- the method is used for the purification of biologically active Vaccinia virus and comprises the following steps:
- the method is used for the purification of biologically active Vaccinia virus and comprises the following steps:
- a physiological salt concentration approximately 150 mM NaCI.
- An appropriate buffer is Phosphate Buffered Saline (PBS), e.g. 0.01 to 0.1 M phosphate, 0.15 M NaCI, pH 7.5.
- PBS Phosphate Buffered Saline
- Tris-NaCI e.g. 0.01 to 0.1 M Tris, 0.15 M
- the method is used for the purification of biologically active Vaccinia virus and comprises the following steps:
- PBS Phosphate Buffered Saline
- Tris-NaCI e.g. 0.01 to 0.1 M Tris, 0.15 M NaCI, pH 8.0, and
- HEPES-NaCI e.g. 0.01 to 0.1 M HEPES, 0.15 M NaCI, pH
- the method is used for the purification of biologically active Vaccinia virus and comprises the following steps:
- An appropriate buffer is Phosphate Buffered Saline (PBS), e.g. 0.01 to 0.1 M phosphate, 0.15 M NaCI, pH 7.5.
- PBS Phosphate Buffered Saline
- Tris-NaCI e.g. 0.01 to 0.1 M Tris, 0.15 M b. Washing of the matrix with a sufficient amount of the loading buffer e.g. to ensure complete elution of all non-binding Vaccinia virus particles and non-binding contaminants, as measured by the return of the 280 nm absorbance signal to the pre-loading baseline, and c. Eluting the Vaccinia virus with an increasing concentration of Low
- the method is used for the purification of biologically active Vaccinia virus and comprises the following steps:
- a Loading a column, membrane, filter or similar solid-phase matrix substituted with a Heparane Sulphate (HS) with a Vaccinia virus preparation dissolved in Phosphate Buffered Saline (PBS), 0.02 M phosphate, 0.15 M NaCI, pH 7.5, b. Washing of the matrix with a sufficient amount of the loading buffer e.g. to ensure complete elution of all non-binding Vaccinia virus particles and non-binding contaminants, as measured by the return of the 280 nm absorbance signal to the pre-loading baseline, and c. Eluting the Vaccinia virus with an increasing concentration of an HS-derived oligosaccharide.
- PBS Phosphate Buffered Saline
- the basic repeating disaccharide unit in HS-derived oligosaccharide is a, (31- ⁇ 4-linked sequence of glucosamine and uronic acid.
- the glucosamine residues are either N-acetylated (GIcNAc) or N-sulphated (GlcNSO3-).
- Other monosaccharide residues e.g. iduronic acid and substitutions may occur, e.g. 2-0-sulphated iduronic acid.
- the oligosaccharide consists of 2 to 10 repeating disaccharide units.
- the oligosaccharide concentration used for elution of the Vaccinia virus particles runs from 0.01 M to 0.5 M in PBS, 0.02 M phosphate, 0.15 M NaCI, pH 7.5.
- the method is used for the purification of biologically active Vaccinia virus and comprises the following steps: a. Loading a column, membrane, filter or similar solid-phase matrix substituted with a Heparane Sulphate (HS) with a Vaccinia virus preparation dissolved in Phosphate Buffered Saline (PBS) 1 0.02 M phosphate, 0.15 M NaCI, pH 7.5, b. Washing of the matrix with a sufficient amount of the loading buffer e.g. to ensure complete elution of all non-binding Vaccinia virus particles and non-binding contaminants, as measured by the return of the 280 nm absorbance signal to the pre-loading baseline, and c.
- HS Heparane Sulphate
- PBS Phosphate Buffered Saline
- the preferred surface protein is A27L
- the preferred peptide is A27L
- the preferred A27L peptide- fragment is fragment containing 4 - 10 amino acid residues of the A27L peptide sequence responsible for the binding between A27L and the HS.
- the peptide concentration used for elution of the Vaccinia virus particles runs from 0.01 M to 0.5 M in PBS,
- the method is used for the purification of biologically active Vaccinia virus and comprises the following steps:
- a Loading a column, membrane, filter or similar solid-phase matrix substituted with a Heparane Sulphate (HS) with a Vaccinia virus preparation dissolved in Phosphate Buffered Saline (PBS), 0.02 M phosphate, 0.15 M NaCI, pH 7.5, b. Washing of the matrix with a sufficient amount of the loading buffer e.g. to ensure complete elution of all non-binding Vaccinia virus particles and non-binding contaminants, as measured by the return of the 280 nm absorbance signal to the pre-loading baseline, and c.
- PBS Phosphate Buffered Saline
- Preferred enzymes are Heparin Lyase I, Il and III.
- the elution is performed by saturation of the column with the enzyme solution. After an appropriate digestion time the unbound complex of Vaccinia virus particles and GAG-residues bound to the Vaccinia virus particles is eluted with PBS, 0.02 M phosphate, 0.15 M NaCI, pH 7.5.
- the Vaccinia virus particle-GAG-residue complex is dissociated with a mild NaCI solution e.g. PBS 0.02 M 1 0.15 M NaCI, pH 7.5 and the GAG-residues are removed by diafiltration.
- Affinity purifications are made applying either column chromatography with e.g. Toyopearls or membrane chromatography using e.g. a membrane (e.g. Sartobind MA 75 (Sartorius)) both of which are substituted with a GAG-ligand (e.g. Heparin or Heparan Sulfate).
- a membrane e.g. Sartobind MA 75 (Sartorius)
- GAG-ligand e.g. Heparin or Heparan Sulfate
- DNA assay showing an additional removal of DNA of appr. 40% in the wash and flow-through.
- NaCI was increased linearly from 0.15 M to 2.0 M.
- the elution started after approximately a total of 20 minutes (4 minutes after starting the gradient).
- the peak contained a high concentration of Vaccinia virus particles as assessed by the Laser Scattering signal used for monitoring of Vaccinia virus particles.
- the eluate was analyzed by a Vaccinia Virus specific ELISA showing a virus recovery rate of appr. 55%.
- Host cell protein was analyzed by use of the BCA total protein assay and revealed a protein recovery of appr. 5% in the eluate.
- Host cell DNA was analyzed by a total DNA assay and revealed appr. 10% DNA in the eluate.
- the membrane is washed with PBS 0.01 M, 0.15 M NaCI, pH 7.5.
- the A280 absorbance signal is used for monitoring of Vaccinia virus particle and the host cell protein concentrations until it returns to baseline (the pre-loading value). The washings are continued for a total of 20 minutes.
- the bound Vaccinia virus particles are eluted by a pH concentration gradient in GBS 0.02 M, 0.15 M NaCI.
- the initial pH is 8.5, increasing to pH 10.5.
- the concentration of NaCI is increased linearly from 0.15 M to 2.0 M.
- the eluate is analyzed by titration for viable (infectious) Vaccinia virus particles by a Tissue Culture cytopatic effect assay (TCID50), for total number of Vaccinia virus particles by a real-time qPCR for Vaccinia DNA, for host cell protein by use of the BCA total protein assay and for host cell DNA by use of a real-time qPCR.
- TID50 Tissue Culture cytopatic effect assay
- the recovery can be >60% and biological activity of the recovered Vaccinia virus can be >75%.
- the membrane is washed with PBS 0.01 M 1 0.15 M NaCI, pH 7.5.
- the A280 absorbance signal is used for monitoring of Vaccinia virus particle and the host cell protein concentrations until it returns to baseline (the pre-loading value). The washings are continued for a total of 20 minutes.
- the elution is performed with a concentration gradient of low- molecular weight heparin (LMW-HP) in PBS 0.1 M, 0.15 M NaCI, pH 7.5. The gradient is run from 0.01 to 0.5 M LMW-Heparin.
- LMW-HP low- molecular weight heparin
- the eluate is analyzed by titration for viable (infectious) Vaccinia virus particles by a Tissue Culture cytopathic effect assay (TCI D50), for total number of Vaccinia virus particles by a real-time qPCR for Vaccinia DNA, for host cell protein by use of the BCA total protein assay and for host cell DNA by use of a real-time qPCR.
- TCI D50 Tissue Culture cytopathic effect assay
- the recovery can be >70% and biological activity of the recovered Vaccinia virus can be >80%.
- the eluate is analyzed by titration for viable (infectious) Vaccinia virus particles by a Tissue Culture cytopatic effect assay (TCI D50), for total number of Vaccinia virus particles by a real-time qPCR for Vaccinia
- the recovery can be >70% and biological activity of the recovered Vaccinia virus can be >80%.
- Example 6 1) Two ml of a highly concentrated Vaccinia virus preparation with approximately 2 x 10 9 virus particles per ml are applied to a Sartobind MA75 Heparin membrane.
- the membrane is washed with PBS 0.01 M, 0.15 M NaCI, pH 7.5.
- the A280 absorbance signal is used for monitoring of Vaccinia virus particle and the host cell protein concentrations until it returns to baseline
- the washings are continued for a total of 20 minutes.
- GAG-residue complex is dissociated with PBS 0.02 M, 0.3 M NaCI, pH 7.5.
- the Heparin-residues are removed by diafiltration.
- TCID50 Tissue Culture cytopatic effect assay
- the recovery can be >70% and biological activity of the recovered Vaccinia virus can be >80%.
- the membrane was washed with PBS 0.01 M, 0.15 M NaCI, pH 7.5.
- the A280 absorbance signal was used for monitoring of Vaccinia virus particle and the host cell protein concentrations until it returned to baseline (the pre-loading value). The washings were continued for a total of 25 minutes.
- the bound Vaccinia virus particles were eluted by a NaCI concentration gradient in PBS 0.01 M, pH 7.5.
- the concentration of NaCI was increased linearly from 0.15 M to 2.0 M.
- the elution started after approximately a total of 30 minutes (5 minutes after starting the gradient).
- the peak contained a high concentration of Vaccinia virus particles as assessed by the Laser Scattering signal used for monitoring of Vaccinia virus particles.
- the eluate was analyzed by a Vaccinia Virus specific ELISA showing a virus recovery rate of approx 40%.
- Host-cell protein was analyzed by use of the BCA total protein assay and showed a protein recovery of approx 5% in the eluate.
- Host-cell DNA was analyzed by a total DNA assay and showed approx 5% DNA in the eluate.
- Betakova T, Wolffe EJ , Moss B Regulation of vaccinia virus morphogenesis: phosphorylation of the A14L and A17L membrane proteins and C-terminal truncation of the Al 7L protein are dependent on the F1OL kinase. J Virol 1999; 73(5):3534-3543.
- Betakova T, Wolffe EJ, Moss B The vaccinia virus A14.5L gene encodes a hydrophobic 53-amino-acid virion membrane protein that enhances virulence in mice and is conserved among vertebrate poxviruses. J Virol 2000; 74(9):4085-4092.
- Betakova T, Wolfe EJ, Moss B Membrane topology of the vaccinia virus A17L envelope protein. Virology 1999; 261 (2):347-356.
- Ho Y, Hsiao JC, Yang MH, Chung CS, Peng YC, Lin TH, Chang W, Tzou DL The oligomeric structure of vaccinia viral envelope protein A27L is essential for binding to heparin and heparan sulfates on cell surfaces: a structural and functional approach using site-specific mutagenesis. J MoI Biol 2005; 349(5):1060-1071.
- Vazquez Ml, Esteban M Identification of functional domains in the 14- kilodalton envelope protein (A27L) of vaccinia virus. J Virol 1999; 73(11 ):9098-9109.
- van EH Hollinshead M, Smith GL: The vaccinia virus A36R protein is a type Ib membrane protein present on intracellular but not extracellular enveloped virus particles. Virology 2000; 271 (1 ):26-36.
- Ward BM 1 Moss B Vaccinia virus A36R membrane protein provides a direct link between intracellular enveloped virions and the microtubule motor kinesin. J Virol 2004; 78(5):2486-2493.
- Senkevich TG Weisberg AS, Moss B: Vaccinia virus E1 OR protein is associated with the membranes of intracellular mature virions and has a role in morphogenesis.
- Senkevich TG, White CL, Koonin EV, Moss B A viral member of the ERV1/ALR protein family participates in a cytoplasmic pathway of disulfide bond formation. Proc Natl Acad Sci U S A 2000; 97(22):12068-12073.
- Blasco R, Moss B Extracellular vaccinia virus formation and cell-to- cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J Virol 1991 ; 65(11 ):5910-5920.
- Roper RL, Moss B Envelope formation is blocked by mutation of a sequence related to the HKD phospholipid metabolism motif in the vaccinia virus F13L protein. J Virol 1999; 73(2):1108-1117.
- Knipe DM Howley PM: Fields Virology, ed Fifth, Philadelphia, USA, Lippincott Williams & Wilkins, a Wolthers Kluwer business, 2007.
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010507827A JP2010526546A (en) | 2007-05-14 | 2008-05-07 | Purification of vaccinia virus and recombinant vaccinia virus vaccines |
AU2008250596A AU2008250596C1 (en) | 2007-05-14 | 2008-05-07 | Purification of Vaccinia virus- and recombinant Vaccinia virus-based vaccines |
CA2676149A CA2676149C (en) | 2007-05-14 | 2008-05-07 | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
EP08749384A EP2152862A1 (en) | 2007-05-14 | 2008-05-07 | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
US12/598,362 US8012738B2 (en) | 2007-05-14 | 2008-05-07 | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
EP21204501.7A EP3988651A1 (en) | 2007-05-14 | 2008-05-07 | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
NZ578960A NZ578960A (en) | 2007-05-14 | 2008-05-07 | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
US12/622,563 US8003364B2 (en) | 2007-05-14 | 2009-11-20 | Purification of vaccinia viruses using hydrophobic interaction chromatography |
US12/622,474 US8003363B2 (en) | 2007-05-14 | 2009-11-20 | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
US13/214,836 US8415132B2 (en) | 2007-05-14 | 2011-08-22 | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
US13/214,979 US8163531B2 (en) | 2007-05-14 | 2011-08-22 | Purification of vaccinia viruses using hydrophobic interaction chromatography |
US13/215,258 US8211686B2 (en) | 2007-05-14 | 2011-08-23 | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
US13/420,892 US8470578B2 (en) | 2007-05-14 | 2012-03-15 | Purification of vaccinia viruses using hydrophobic interaction chromatography |
US13/906,541 US9109201B2 (en) | 2007-05-14 | 2013-05-31 | Purification of vaccinia viruses using hydrophobic interaction chromatography |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92441307P | 2007-05-14 | 2007-05-14 | |
US60/924,413 | 2007-05-14 |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12589362 A-371-Of-International | 2008-05-07 | ||
US12/598,362 A-371-Of-International US8012738B2 (en) | 2007-05-14 | 2008-05-07 | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
US12/622,474 Continuation-In-Part US8003363B2 (en) | 2007-05-14 | 2009-11-20 | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
US13/215,258 Continuation US8211686B2 (en) | 2007-05-14 | 2011-08-23 | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008138533A1 true WO2008138533A1 (en) | 2008-11-20 |
Family
ID=39579984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/003679 WO2008138533A1 (en) | 2007-05-14 | 2008-05-07 | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
Country Status (7)
Country | Link |
---|---|
US (2) | US8012738B2 (en) |
EP (2) | EP2152862A1 (en) |
JP (2) | JP2010526546A (en) |
AU (1) | AU2008250596C1 (en) |
CA (1) | CA2676149C (en) |
NZ (1) | NZ578960A (en) |
WO (1) | WO2008138533A1 (en) |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009123348A1 (en) * | 2008-03-31 | 2009-10-08 | 日本たばこ産業株式会社 | Method for concentration of virus |
WO2010128100A1 (en) * | 2009-05-08 | 2010-11-11 | Glaxosmithkline Biologicals S.A. | Method for producing virus from cell culture involving homogenization |
US8003364B2 (en) | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
WO2012010280A1 (en) | 2010-07-20 | 2012-01-26 | Bavarian Nordic A/S | Method for harvesting expression products |
US20120156757A1 (en) * | 2010-12-15 | 2012-06-21 | Millipore Corporation | Purification of immunogens using a non-polysaccharide matrix |
US8609392B2 (en) | 2009-05-12 | 2013-12-17 | Transgene S.A. | Method for orthopoxvirus production and purification |
WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
WO2017060650A1 (en) | 2015-10-08 | 2017-04-13 | Jean-Marc Limacher | Anti-tumoral composition |
WO2017191147A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
WO2018122088A1 (en) | 2016-12-28 | 2018-07-05 | Transgene Sa | Oncolytic viruses and therapeutic molecules |
WO2018210804A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
WO2018211419A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
WO2018234506A2 (en) | 2017-06-21 | 2018-12-27 | Transgene Sa | Personalized vaccine |
WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | Oncolytic viruses expressing agents targeting metabolic immune modulators |
EP3552615A1 (en) | 2014-07-16 | 2019-10-16 | Transgene SA | Oncolytic virus for expression of immune checkpoint modulators |
WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
WO2020049001A1 (en) | 2018-09-03 | 2020-03-12 | Bioinvent International Ab | Novel antibodies and nucleotide sequences, and uses thereof |
WO2020049151A1 (en) | 2018-09-06 | 2020-03-12 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
WO2020136235A1 (en) | 2018-12-28 | 2020-07-02 | Transgene Sa | M2-defective poxvirus |
EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
WO2021180943A1 (en) | 2020-03-12 | 2021-09-16 | Bavarian Nordic A/S | Compositions improving poxvirus stability |
WO2022013221A1 (en) | 2020-07-13 | 2022-01-20 | Transgene | Treatment of immune depression |
WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
WO2023025899A2 (en) | 2021-08-26 | 2023-03-02 | Transgene | Delivery system for targeting genes of the interferon pathway |
WO2023046777A1 (en) | 2021-09-22 | 2023-03-30 | Bioinvent International Ab | Novel combinations of antibodies and uses thereof |
WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
WO2024003238A1 (en) | 2022-06-29 | 2024-01-04 | Bavarian Nordic A/S | Epstein-barr-virus vaccine |
WO2024003353A1 (en) | 2022-07-01 | 2024-01-04 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
WO2024003239A1 (en) | 2022-06-29 | 2024-01-04 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN |
WO2024038175A1 (en) | 2022-08-18 | 2024-02-22 | Transgene | Chimeric poxviruses |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ578960A (en) | 2007-05-14 | 2012-11-30 | Bavarian Nordic As | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
RU2537000C1 (en) * | 2013-08-07 | 2014-12-27 | Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) | Method of purification of vaccinia virus or its recombinant versions |
CN110564700B (en) * | 2018-06-06 | 2023-08-15 | 杭州功楚生物科技有限公司 | Oncolytic vaccinia virus carrying limulus lectin gene, construction method and application |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003054175A1 (en) * | 2001-12-20 | 2003-07-03 | Bavarian Nordic A/S | Method for the recovery and purification of poxviruses from infected cells |
US20030165477A1 (en) * | 2000-04-14 | 2003-09-04 | Jean-Marc Balloul | Poxvirus with targeted infection specificity |
US20070071769A1 (en) * | 1995-07-04 | 2007-03-29 | Gsf-Forschungszentrum Fur Umwelt Und Gesundheit Gmbh | Recombinant MVA virus, and the use thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE787901A (en) | 1971-09-11 | 1972-12-18 | Freistaat Bayern Represente Pa | ANTIVARIOLIC VACCINE |
GB9804632D0 (en) * | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
GB9925432D0 (en) * | 1999-10-27 | 1999-12-29 | Univ London | Virus preparation |
JP2001190273A (en) * | 2000-01-14 | 2001-07-17 | Jsr Corp | Particle for concentrating virus, method for concentrating and detecting the virus by using the particle |
JP4802401B2 (en) * | 2000-11-07 | 2011-10-26 | トランスジェン・ソシエテ・アノニム | Poxvirus with targeted infection specificity |
ES2256323T5 (en) | 2000-11-23 | 2016-11-21 | Bavarian Nordic A/S | Variant of the Modified Vaccinia Ankara virus |
HUP0402179A3 (en) | 2001-12-10 | 2012-09-28 | Bavarian Nordic As | Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions |
ATE545699T1 (en) * | 2003-06-18 | 2012-03-15 | Genelux Corp | MODIFIED RECOMBINANT VACCINIA VIRUSES AND USES THEREOF |
US8003363B2 (en) | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
US8003364B2 (en) | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
NZ578960A (en) | 2007-05-14 | 2012-11-30 | Bavarian Nordic As | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
-
2008
- 2008-05-07 NZ NZ578960A patent/NZ578960A/en unknown
- 2008-05-07 CA CA2676149A patent/CA2676149C/en active Active
- 2008-05-07 EP EP08749384A patent/EP2152862A1/en not_active Ceased
- 2008-05-07 JP JP2010507827A patent/JP2010526546A/en active Pending
- 2008-05-07 WO PCT/EP2008/003679 patent/WO2008138533A1/en active Application Filing
- 2008-05-07 AU AU2008250596A patent/AU2008250596C1/en active Active
- 2008-05-07 EP EP21204501.7A patent/EP3988651A1/en active Pending
- 2008-05-07 US US12/598,362 patent/US8012738B2/en active Active
-
2011
- 2011-08-23 US US13/215,258 patent/US8211686B2/en active Active
-
2014
- 2014-12-19 JP JP2014257207A patent/JP6152085B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070071769A1 (en) * | 1995-07-04 | 2007-03-29 | Gsf-Forschungszentrum Fur Umwelt Und Gesundheit Gmbh | Recombinant MVA virus, and the use thereof |
US20030165477A1 (en) * | 2000-04-14 | 2003-09-04 | Jean-Marc Balloul | Poxvirus with targeted infection specificity |
WO2003054175A1 (en) * | 2001-12-20 | 2003-07-03 | Bavarian Nordic A/S | Method for the recovery and purification of poxviruses from infected cells |
Non-Patent Citations (6)
Title |
---|
BRODER CHRISTOPHER C ET AL: "Recombinant vaccinia viruses: Design, generation, and isolation", MOLECULAR BIOTECHNOLOGY, vol. 13, no. 3, 15 December 1999 (1999-12-15), pages 223 - 245, XP002491383, ISSN: 1073-6085 * |
CHUNG C-S ET AL: "A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 72, no. 2, 1 February 1998 (1998-02-01), pages 1577 - 1585, XP002353165, ISSN: 0022-538X * |
HARRER E ET AL: "THERAPEUTIC VACCINATION OF HIV-1-INFECTED PATIENTS ON HAART WITH A RECOMBINANT HIV-1 NEF-EXPRESSING MVA: SAFETY, IMMUNOGENICITY AND INFLUENCE ON VIRAL LOAD DURING TREATMENT INTERRUPTION", ANTIVIRAL THERAPY, MTM PUBLICATIONS, LONDON, GB, vol. 10, no. 2, 1 January 2005 (2005-01-01), pages 285 - 300, XP008051260, ISSN: 1359-6535 * |
See also references of EP2152862A1 * |
SHEN Y ET AL: "Fighting Cancer with Vaccinia Virus: Teaching New Tricks to an Old Dog", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 11, no. 2, 1 February 2005 (2005-02-01), pages 180 - 195, XP004723672, ISSN: 1525-0016 * |
ZAHN ASTRID ET AL: "Hepatitis C virus and hepatitis B virus bind to heparin: purification of largely IgG-free virions from infected plasma by heparin chromatography", JOURNAL OF GENERAL VIROLOGY, vol. 86, no. Part 3, March 2005 (2005-03-01), pages 677 - 685, XP002491382, ISSN: 0022-1317 * |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8003364B2 (en) | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
US8163531B2 (en) | 2007-05-14 | 2012-04-24 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
US8470578B2 (en) | 2007-05-14 | 2013-06-25 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
US9109201B2 (en) | 2007-05-14 | 2015-08-18 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
WO2009123348A1 (en) * | 2008-03-31 | 2009-10-08 | 日本たばこ産業株式会社 | Method for concentration of virus |
WO2010128100A1 (en) * | 2009-05-08 | 2010-11-11 | Glaxosmithkline Biologicals S.A. | Method for producing virus from cell culture involving homogenization |
US20120058145A1 (en) * | 2009-05-08 | 2012-03-08 | Bruno Rene Andre | Method for producing virus from cell culture involving homogenization |
JP2012525830A (en) * | 2009-05-08 | 2012-10-25 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Method for producing virus from cell culture including homogenization |
US8609392B2 (en) | 2009-05-12 | 2013-12-17 | Transgene S.A. | Method for orthopoxvirus production and purification |
US9012198B2 (en) | 2009-05-12 | 2015-04-21 | Transgene S.A. | Method for orthopoxvirus production and purification |
US10087423B2 (en) | 2010-07-20 | 2018-10-02 | Bavarian Nordic A/S | Method for harvesting expression products |
WO2012010280A1 (en) | 2010-07-20 | 2012-01-26 | Bavarian Nordic A/S | Method for harvesting expression products |
US20120156757A1 (en) * | 2010-12-15 | 2012-06-21 | Millipore Corporation | Purification of immunogens using a non-polysaccharide matrix |
EP3552615A1 (en) | 2014-07-16 | 2019-10-16 | Transgene SA | Oncolytic virus for expression of immune checkpoint modulators |
WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
WO2017060650A1 (en) | 2015-10-08 | 2017-04-13 | Jean-Marc Limacher | Anti-tumoral composition |
WO2017191147A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
WO2018122088A1 (en) | 2016-12-28 | 2018-07-05 | Transgene Sa | Oncolytic viruses and therapeutic molecules |
WO2018210804A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
US11052147B2 (en) | 2017-05-15 | 2021-07-06 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
WO2018211419A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
US11306292B2 (en) | 2017-05-15 | 2022-04-19 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
WO2018234506A2 (en) | 2017-06-21 | 2018-12-27 | Transgene Sa | Personalized vaccine |
US11969462B2 (en) | 2017-06-21 | 2024-04-30 | Transgene | Personalized vaccine |
WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | Oncolytic viruses expressing agents targeting metabolic immune modulators |
WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
WO2020049001A1 (en) | 2018-09-03 | 2020-03-12 | Bioinvent International Ab | Novel antibodies and nucleotide sequences, and uses thereof |
WO2020049151A1 (en) | 2018-09-06 | 2020-03-12 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
KR20210110838A (en) | 2018-12-28 | 2021-09-09 | 트랜스진 에스.에이. | M2 defective poxvirus |
WO2020136235A1 (en) | 2018-12-28 | 2020-07-02 | Transgene Sa | M2-defective poxvirus |
EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
WO2021130210A1 (en) | 2019-12-23 | 2021-07-01 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
KR20220119637A (en) | 2019-12-23 | 2022-08-30 | 트랜스진 | How to Design a Recombinant Poxvirus for a Therapeutic Vaccine |
WO2021180943A1 (en) | 2020-03-12 | 2021-09-16 | Bavarian Nordic A/S | Compositions improving poxvirus stability |
WO2022013221A1 (en) | 2020-07-13 | 2022-01-20 | Transgene | Treatment of immune depression |
KR20230038496A (en) | 2020-07-13 | 2023-03-20 | 트랜스진 | treatment of immunosuppression |
WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
WO2023025899A2 (en) | 2021-08-26 | 2023-03-02 | Transgene | Delivery system for targeting genes of the interferon pathway |
WO2023046777A1 (en) | 2021-09-22 | 2023-03-30 | Bioinvent International Ab | Novel combinations of antibodies and uses thereof |
WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
WO2024003238A1 (en) | 2022-06-29 | 2024-01-04 | Bavarian Nordic A/S | Epstein-barr-virus vaccine |
WO2024003239A1 (en) | 2022-06-29 | 2024-01-04 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN |
WO2024003353A1 (en) | 2022-07-01 | 2024-01-04 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
WO2024038175A1 (en) | 2022-08-18 | 2024-02-22 | Transgene | Chimeric poxviruses |
Also Published As
Publication number | Publication date |
---|---|
CA2676149C (en) | 2016-06-21 |
AU2008250596B2 (en) | 2010-07-08 |
JP2015091248A (en) | 2015-05-14 |
US20110300181A1 (en) | 2011-12-08 |
CA2676149A1 (en) | 2008-11-20 |
US8012738B2 (en) | 2011-09-06 |
EP2152862A1 (en) | 2010-02-17 |
US20100129326A1 (en) | 2010-05-27 |
JP6152085B2 (en) | 2017-06-21 |
EP3988651A1 (en) | 2022-04-27 |
AU2008250596A1 (en) | 2008-11-20 |
US8211686B2 (en) | 2012-07-03 |
AU2008250596C1 (en) | 2010-11-25 |
AU2008250596A2 (en) | 2009-10-08 |
NZ578960A (en) | 2012-11-30 |
JP2010526546A (en) | 2010-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2676149C (en) | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines | |
US8415132B2 (en) | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines | |
US9109201B2 (en) | Purification of vaccinia viruses using hydrophobic interaction chromatography | |
RU2489486C2 (en) | Method to produce pox viruses and compositions of pox viruses | |
Wolff et al. | Capturing of cell culture‐derived modified Vaccinia Ankara virus by ion exchange and pseudo‐affinity membrane adsorbers | |
US7056723B2 (en) | Method for the recovery and purification of poxviruses from infected cells | |
CA2768562A1 (en) | Enzymatic composition for the digestion of chicken embryos | |
CN104812894B (en) | Novel MVA virus and uses thereof | |
CN116218879A (en) | Monovalent broad-spectrum orthopoxvirus mRNA vaccine and application thereof | |
CN105829537B (en) | Compositions and methods vectors for inducing enhanced immune responses using poxvirus vectors | |
Zhu et al. | The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes | |
WO2004087047A2 (en) | Mutants of replication competent vaccinia virus | |
WO2004024756A2 (en) | Orthopoxvirus antigens and use thereof | |
Wang et al. | Characterization of an attenuated TE3L-deficient vaccinia virus Tian Tan strain | |
EP1398380A1 (en) | Orthopoxvirus antigens and use thereof | |
CA3052895A1 (en) | Vaccinia virus vectors related to modified vaccinia ankara (mva) with extensive genomic symmetries |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08749384 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2676149 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008250596 Country of ref document: AU Ref document number: 578960 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2008250596 Country of ref document: AU Date of ref document: 20080507 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12598362 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2008749384 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008749384 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010507827 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |